Analyst rating updates for Krystal Biotech, including a buy rating from TD Cowen and a consensus rating from MarketBeat.
3 reports, 2 independent
Updated Oct 16
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst rating updates for Krystal Biotech, including a buy rating from TD Cowen and a consensus rating from MarketBeat.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.MarketBeat expanded its analyst ratings comparison to include Applied Therapeutics.1 source
TD Cowen raised its price target and gave a buy rating for Krystal Biotech, while Jefferies reiterated buy status.1 source
Keep exploring
The entities involved
-
Krystal Biotech, Inc.
biotechnology company
Nothing else this week.
-
MarketBeat
American personal finance blog
Nothing else this week.
-
TD Cowen
American investment bank
-
Jefferies Financial Group
American financial services company
Nothing else this week.
Related events
- MarketBeat reported the stock's average rating as Benchmark and Jefferies reiterated buy ratings for Bright Minds Biosciences Inc.
- MarketBeat reported consensus rating for Hikma Pharmaceuticals, while Jefferies increased its target price and gave a buy rating. Berenberg Bank reaffirmed its buy rating, and Citigroup restated a buy rating.
- MarketBeat is reporting on consensus ratings for Aehr Test Systems, a company whose stock trades on the Nasdaq exchange.
- MarketBeat provided average ratings and target prices, while Jefferies Financial Group began coverage with a buy rating for Crane NXT.
- Needham & Company raised its price objective and issued a buy rating for Ceragon Networks, with MarketBeat reporting consensus data.